Cardiogen

Quickstart Highlights

Cardiogen is a synthetic cardiovascular bioregulator tetrapeptide (AEDR: Ala‑Glu‑Asp‑Arg) studied for its cellular repair and cardioprotective properties. Preclinical research demonstrates Cardiogen enters cells and modulates fundamental survival pathways, supporting cytoskeletal integrity and reducing apoptosis in stressed cardiac tissue while paradoxically encouraging apoptosis in abnormal cells. This educational protocol presents a once-daily subcutaneous 20-day course (repeated two to three times per year) for research applications.

• Reconstitute: Add 2.0 mL bacteriostatic water (BAC) per labelled 20 mg vial. Calculations assume a final volume of 2.0 mL and nominal 10 mg/mL.
• Typical daily range: 200–500 mcg once daily for a 20-day course (200 mcg for Days 1–3, then 500 mcg); repeat 2–3 times per year.
• Scale conversion: At 10 mg/mL, 1 U-100 unit = 0.01 mL = 0.1 mg (100 mcg). Verify the actual device markings and calibration.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Protocol Overview

Concise summary of the 20-day course regimen.

• Goal: Support cellular repair mechanisms and cardiovascular tissue resilience in research models.
• Schedule: One daily subcutaneous injection for a 20-day course (10 days minimum); repeat two to three times per year with at least 3 months between courses.
• Dose Range: 200–500 mcg daily; 200 mcg for Days 1–3, then 500 mcg.
• Reconstitution: 2.0 mL BAC per labelled 20 mg vial; nominal 10 mg/mL under the stated final-volume assumption.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested 20-day course (Khavinson-style bioregulator schedule).

• Start: 200 mcg daily for Days 1–3 to assess tolerance.
• Target: 500 mcg daily from Day 4 through Day 20.
• Frequency: Once per day (subcutaneous).
• Course Length: 20 days standard (10 days minimum); 2–3 courses per year with at least 3 months between courses. Do not extend continuously.
• Timing: Any consistent time; rotate injection sites daily.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 2–4 weeks with bacteriostatic water; avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Consider 30‑ or 50‑unit insulin syringes for improved precision with small volumes.

How This Works

Cardiogen functions as a gene expression bioregulator operating at the cellular and nuclear level. Research demonstrates it upregulates structural proteins including actin, tubulin, vimentin, and nuclear lamins, thereby supporting cytoskeletal integrity and nuclear matrix function. This mechanism promotes cell repair and reduces programmed cell death in stressed or damaged tissue. Notably, Cardiogen appears to suppress overactive p53‑mediated apoptosis signals under stress conditions, allowing healthy cells to survive injury while paradoxically encouraging apoptosis in abnormal or cancerous cells. In rodent cardiac studies, daily Cardiogen administration reduced post‑myocardial infarction mortality approximately threefold, preserved cardiac tissue architecture, and maintained higher glycogen reserves in heart muscle cells. The peptide enhances metabolic resilience by improving mitochondrial integrity and preserving energy stores during stress.

Potential Benefits & Side Effects

Observations from preclinical research models.

• Demonstrated cardioprotective effects in rodent myocardial infarction models, reducing mortality and necrotic tissue formation.
• Stimulates cardiomyocyte and fibroblast proliferation while decreasing pro‑apoptotic factors, potentially reducing pathological fibrosis.
• Shows selective dual action: protects healthy cells while promoting apoptosis in tumor cells (demonstrated in M‑1 sarcoma models).
• Preserves metabolic function in cardiac tissue, maintaining glycogen stores and mitochondrial integrity during stress.
• No human clinical data available; all evidence derives from laboratory and animal research.
• Generally well tolerated in preclinical models; occasional mild injection‑site reactions possible with subcutaneous administration.

Lifestyle Factors

Complementary strategies for research protocols.

• Maintain consistent timing of daily injections to establish stable plasma levels.
• Document any observable effects or changes systematically throughout the research period.
• Ensure proper cold‑chain maintenance for all peptide storage to preserve potency.
• Consider splitting into sterile aliquots if extended use periods require multiple vial openings.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

• Clean the vial stopper and skin with alcohol; allow to dry completely before proceeding.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, upper arms) to avoid lipohypertrophy.
• Apply gentle pressure post‑injection with clean gauze; do not rub the site.
• Dispose of used syringes immediately in a proper sharps container.

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Amino Labs